NCT01605396View on ClinicalTrials.gov

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 4, 2012

Primary Completion Date

February 19, 2014

Study Completion Date

March 15, 2018

Conditions
Breast Neoplasms
Interventions
DRUG

Ridaforolimus

Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.

DRUG

Dalotuzumab

Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.

DRUG

Exemestane

Exemestane 25 mg tablet administered PO QD.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01605396 - A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | Biotech Hunter | Biotech Hunter